Biotech company Pharming Group NV announces a new analyst report from Roth Capital Partners.
PHARM.AS: Increased Ruconest Focus Should Drive Upside
Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners.
Sijmen de Vries, CEO: T: +31 524 7400
“This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature”